NDA 021160 · Fresenius Medcl Care
Phoslo Gelcaps
Calcium Acetate · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Jun 22, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2001
Apr 2, 2001
Approved uses
1
Original approval plus efficacy supplements
Registered trials
3
1 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- PHOSLO GELCAPS · CALCIUM ACETATE 667MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued · TE AB
- PHOSLO · CALCIUM ACETATE 333.5MG · CAPSULE, ORAL · Discontinued
- PHOSLO · CALCIUM ACETATE 667MG · CAPSULE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Phoslo Gelcaps" as an intervention, any sponsor and status, largest first.
- EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease)Pivotal-lookingCompleted
Nabi BiopharmaceuticalsIndustry
NCT00211978 · 110 participants · Start May 2005 · Primary completion Jun 2006
Drug: calcium acetate; placebo · For: Hyperphosphatemia; Kidney Failure
Sites: San Antonio, Texas
Akebia TherapeuticsIndustry
NCT04299633 · 54 participants · Start Jun 15, 2020 · Primary completion Aug 2, 2020
Drug: Vadadustat; Sevelamer carbonate and 2 more · For: Healthy Volunteers
Sites: Québec, Canada
Fresenius Medical Care North AmericaIndustry
NCT00742820 · 46 participants · Start Aug 2008 · Primary completion Nov 2008
Drug: Calcium Acetate Oral Solution 667 mg per 5 mL; Calcium Acetate 667 mg GelCaps · For: Hyperphosphatemia
Sites: Cincinnati, Ohio
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Fresenius Medcl Care · Also marketed as Phoslo
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.